Consistent with this, we determined treatment with an inhibitor of Survivin, but not Xiap1, prevented relapse during TKI treatment and after therapy discontinuation in a murine CML model. This evidence concerns the gene BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive.